TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the ParadiseTOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise

Otsuka Medical Devices/Otsuka Pharmaceutical: Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and Commercially Available in Japan

2026/03/02 08:15
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and will conduct co-promotion with Otsuka Pharmaceutical.

The Paradise uRDN system was developed by Recor Medical, Inc. (Recor Medical), a U.S.-based subsidiary of Otsuka Medical Devices. This system is indicated for resistant hypertension patients whose blood pressure remains above target despite the use of three antihypertensive medications of different classes, including a diuretic.

Otsuka Medical Devices is introducing ultrasound renal denervation treatment to Japan for the first time. This novel treatment is designed to lower blood pressure by reducing overactivity of the sympathetic nerves surrounding the renal arteries.

With this insurance coverage, Paradise uRDN system becomes available as a new treatment option for resistant hypertension. Under a co-promotion framework, Otsuka Medical Devices and Otsuka Pharmaceutical will leverage Otsuka Pharmaceutical’s established expertise in the cardiovascular and renal fields to supply appropriate treatment options suited to patient conditions. The system will be prescribed by physicians to patients as defined in the guidelines for the proper use of renal denervation systems.

Kazuomi Kario, President of the Japanese Society of Hypertension and Professor of Cardiovascular Medicine at Jichi Medical University, commented, “Resistant hypertension carries an extremely high risk of leading to serious complications, such as cerebrovascular and cardiovascular diseases and renal failure. Being able to provide appropriate treatment opportunities to patients in need through this insurance coverage marks a significant step forward. Furthermore, the Japanese Society of Hypertension, the Japanese Association of Cardiovascular Intervention and Therapeutics, and the Japanese Circulation Society will work together to ensure that proper and safe treatment is delivered based on the facility requirements and patient eligibility criteria outlined in the guidelines for the proper use of renal denervation systems, which were formulated by our three societies.”

Makoto Inoue, President and Representative Director, CEO of Otsuka Holdings Co., Ltd., and President and Representative Director of Otsuka Pharmaceutical stated, “I am delighted that we can provide a new option to address the medical challenge of resistant hypertension by leveraging the know-how cultivated through the Otsuka group’s pharmaceutical business. Moving forward, we will bring together the collective strength of the Otsuka group to deliver optimal solutions for patients and consumers, as we strive to contribute to the total healthcare of every individual.”

“Paradise uRDN system received approval from the U.S. Food and Drug Administration (FDA) in 2023.* We are extremely pleased that patients in Japan with resistant hypertension now have access to this new treatment option under insurance coverage. We have built a framework with Otsuka Pharmaceutical to ensure this treatment reliably reaches patients in need, and we will continue to contribute to the health of patients and the advancement of medical care.” said Noriko Tojo, President and Representative Director of Otsuka Medical Devices.

Guided by the corporate philosophy of Otsuka-people creating new products for better health worldwide, Otsuka Medical Devices and Otsuka Pharmaceutical will continue to make every effort to deliver new value to address unmet medical needs.

*In the U.S, Paradise uRDN system received FDA approval in November 2023 as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient’s blood pressure.

About Otsuka Medical Devices
https://www.omd.otsuka.com/en/

About Recor Medical
https://www.recormedical.com/

About Otsuka Pharmaceutical
https://www.otsuka.co.jp/en/

Contacts

Otsuka Medical Devices
Inquiry form
+81-3-6361-7459

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0003269
$0.0003269$0.0003269
-0.30%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Neom terminates $1bn tunnel contract at heart of The Line

Neom terminates $1bn tunnel contract at heart of The Line

Saudi Arabia’s Neom has cancelled a roughly $1 billion tunnelling contract at the heart of its flagship “The Line” giga-project, according to public documents.
Share
Agbi2026/03/18 11:28
Gold continues to hit new highs. How to invest in gold in the crypto market?

Gold continues to hit new highs. How to invest in gold in the crypto market?

As Bitcoin encounters a "value winter", real-world gold is recasting the iron curtain of value on the blockchain.
Share
PANews2025/04/14 17:12
These Are The XRP Price Targets You Need To Know Now: Cubic Analytics Founder

These Are The XRP Price Targets You Need To Know Now: Cubic Analytics Founder

Cubic Analytics founder Caleb Franzen says XRP is entering a decisive phase after months of compression, with the price structure implying a path toward the $6–$11 zone so long as the market defends what he calls the key risk line at $2.68. XRP Price Targets In a wide-ranging discussion on the Thinking Crypto podcast with host Tony Edward, Franzen stressed that his conclusions are grounded in “price, structure, and statistical signals” rather than narrative. “It’s the chart itself. It’s the structure itself,” he said. “So long as we stay above $2.68, we’re going much higher.” Franzen’s XRP view comes out of the same template he applies across digital assets: identify trend integrity, map the impulse-consolidation rhythm, and translate it into a ladder of Fibonacci extension targets on a logarithmic scale. In XRP’s case, he argues the market traced higher highs and then “tightened up” into a controlled series of lower highs—what he calls a classic volatility coil that “allows price to reset… for the next leg higher.” Related Reading: Social Media Turns Bearish On XRP: Is This A Buy Signal? He then anchors objective targets to that structure: using the most recent consolidation leg, he cites the 161.8% extension near roughly $4.40 and the 261.8% extension around $6. From the larger Q1 swing—Q1 highs to Q1 lows—he adds a second band of objectives at approximately $5.40 and $11.55. The message, in his words: “Those are the price targets that you have to be aware of if you’re holding and investing in XRP… so long as we stay above $2.68.” Risk management is central to how Franzen frames the trade. Rather than a maximalist forecast, he sets a clear invalidation level and treats it as a mechanical decision point. “If we fall below $2.68, you can get stopped out. You can reduce some of your exposure. You can slow down your DCA,” he said. “It’s okay to be wrong. It’s just not okay to stay wrong.” The Macro Angle Although the podcast also covered Bitcoin, Ethereum and Solana, Franzen’s macro and cross-asset framework is meant to contextualize, not overshadow, the XRP setup. He repeatedly described himself as “time agnostic,” declining to pin outcomes to a specific month or quarter and insisting that the tape, not the calendar, dictates probability. “I’ve been sharing [cycle] targets since the middle of 2023,” he noted, adding that the prudent path is to keep raising targets within an uptrend while letting invalidation handle the rest. That stance is informed by what he characterizes as resilient, supportive macro conditions—good enough for risk assets to trend without demanding a weak US dollar as a crutch. He pointed to strong real activity data and improving earnings assumptions as evidence that risk appetite is not being forced; it’s developing naturally. Related Reading: XRP Ready For $9 Blast — ‘Break $3.10 And It’s Game Over,’ Says Analyst Among the specific markers he flagged: Q2 real GDP growth at 3.8% with expectations of roughly 3.9% for Q3; prime-age unemployment near historic lows at about 3.8%; labor force participation rising; and both real and nominal wage growth, with wages around 4.1% year over year. In credit, he underscored tight spreads and high-yield corporates printing multi-year highs—“and if we adjust them for the dividend yield, they’re trading at all-time highs”—a combination that, in his experience, does not occur when markets are bracing for imminent stress. “As we’re looking at the weight of the evidence here, everything is coming together,” he said. “Higher highs and higher lows, increasing risk appetite, decent macro conditions, the Fed is cutting interest rates… We have to continue to have an upward bias.” That macro lens matters for XRP, he argues, because it reinforces the primacy of structure over story. He criticized a common assumption that crypto rallies must coincide with a falling dollar, highlighting that the US Dollar Index (DXY) has been roughly flat since mid-April while Bitcoin—and, by extension, broader crypto beta—advanced materially. He also described a composite lens that prices Bitcoin against a basket of global currencies (effectively offsetting BTC/USD by DXY) and said that index is making fresh all-time highs too, reflecting “weak global fiat currencies, not necessarily just a weak dollar.” The implication for XRP: if the broader liquidity and risk backdrop continues to reward trend persistence, then the technical coil and extension ladder have a cleaner runway. At press time, XRP traded at $2.8593. Featured image created with DALL.E, chart from TradingView.com
Share
NewsBTC2025/10/08 21:30